

This document is aligned to the `Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

### **SECTION 1: PERSONAL DETAILS**

First Name Andreas

Last Name Wicki

Organisation / Company University and University Hospital Zürich

Country of Organisation /

Company

Switzerland

Committee Human Medicines Expert Committee (HMEC)

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.

Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.

Wicki Andreas 17. 6. 2024 1 / 11



### **SECTION 2: PUBLIC DECLARATION OF INTERESTS**

## 2.1 Employment

No ○ Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Wicki Andreas 17. 6. 2024 2 / 11



#### 2.2 Consultancy

No • Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Company

Period

Product

Therapeutic Indication

Funding

General Role / Area of Activity

11/2023 - Navignostics TODAY

> ${\it UZH-Diagnostics\ start-up}$ developping cytometry-based (IMC) diagnostic tools for personalized oncology

Wicki Andreas 17, 6, 2024 3 / 11



### 2.3 Strategic Advisory Role

No Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/ expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.6 Principal Investigator. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

Wicki Andreas 17. 6. 2024 4 / 11



### 2.4 Current Financial Interests

No Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/ pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursement of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

Wicki Andreas 17. 6. 2024 5 / 11



## 2.5 Patent No O Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

Wicki Andreas 17. 6. 2024 6 / 11



## 2.6 Principal Investigator

○ No **⊙** Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial. Involvement in Data Safety Monitoring Committee should be included in this section.

Period	Company	Product	Therapeutic Indication	Funding
			General Role / Area of Activity	
01/2019 - 03/2021	Swiss Tumor Profiler Consortium (University Hospital Basel, University Hospital Zurich, University of Zurich, ETH Zurich, F. Hoffmann-La Roche)	none	observational trial investigating solid and liquid tumor samples on 6 experimental platforms	yes

Wicki Andreas 17. 6. 2024 7 / 11



## 2.7 Investigator • No O Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

Wicki Andreas 17. 6. 2024 8 / 11



### 2.8 Grant / Funding to organisation/institution

○ No ● Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

X

Name of Pharmaceutical Company

POP consortium (University of Zurich, University Hospital Zurich, F. Hoffmann-La Roche)

**Subject Matter** 

Using real world data to model therapy response

Amount of Money (CHF)

1'500'000

Funding paid into an institutional account with shared power of disposition?

yes

Wicki Andreas 17. 6. 2024 9 / 11



#### 2.9 Any other interests or facts

○ No ● Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.

Χ

### Please specify

Vice-Chair of the Scientific Committee of the Swiss Group for Clinical Cancer Research

SAKK is a non-for-profit organisation running clinical cancer trials in Switzerland. SAKK members are Swiss Hospitals and University Clinics. The Scientific Committee judges the scientific value of studies proposed to run within the SAKK network.

Wicki Andreas 17, 6, 2024 10 / 11